TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01851005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Infusion of dexmedetomidine (0.4 ug/kg/hr)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Infusion of dexmedetomidine (0.4 ug/kg/hr)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Control Vol% to maintain BIS 40\~45

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Control Vol% to maintain BIS 40\~45

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol and Remifentanil
Description: Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Remifentanil
Description: Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Use as placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Use as placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: 0.8 mg/kg for induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: 0.8 mg/kg for induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: 0.8 mg/kg for induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: 0.8 mg/kg for induction
Study: NCT02711657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibrocyte measurement and lung function test.
Study: NCT03508557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning tools
Description: Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
Study: NCT02362399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: single oral dose of 50 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: single oral dose of placebo tablet
Study: NCT04298255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Round Spermatid Injection (ROSI)
Description: In Vitro Fertilization using Round Spermatid Injection (ROSI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half ROSI-half Sperm Donor Fertilization
Description: Half ROSI-half Sperm Donor Fertilization
Study: NCT01752933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
Study: NCT03352115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 5 day course of oral prednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo syrup
Study: NCT05090449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone (HIGROTON® 50)
Description: Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan (COZZAR®)
Description: Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A1+ A2 Co-administration of Chlorthalidone and Losartan
Description: 50mg chlorthalidone + 100 mg losartan potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone + Losartan Fixed-Dose combination
Description: Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
Study: NCT00610428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Prochlorperazine 5 mg
Description: Inhaled Prochlorperazine 5 mg
Study: NCT03457727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
Study: NCT01217567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staples left, subcuticular suture right
Description: Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staples left, subcuticular suture right
Description: Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcuticular suture left side and staples right
Description: Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
Study: NCT00610428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Staccato Prochlorperazine 10 mg
Description: Inhaled Prochlorperazine10 mg
Study: NCT01217567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcuticular suture left side and staples right
Description: Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
Study: NCT02908607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal imaging
Description: Examination of the cervix by thermal imaging camera
Study: NCT02284152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: infant-led feeding
Description: mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
Study: NCT01266759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone Acetate tablets - 5mg
Description: Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
Study: NCT01692470

Intervention type: DRUG
Intervention: No intervention
Description: Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
Study: NCT04117958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 199
Description: AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 199
Description: AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
Study: NCT02937285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a
Description: Subcutaneous injection of 44µg 3 times a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1a
Description: Subcutaneous injection of 44µg 3 times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg / m² monthly infusion for 6 months
Study: NCT02599610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital vaginal examination
Description: Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasound examination
Description: Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
Study: NCT00391118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02606864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502)
Description: Oral Intake of 4 x 30 mg nifurtimox tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (BAYa2502)
Description: Oral Intake of 4 x 30 mg nifurtimox tablets
Study: NCT02034500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB
Study: NCT02376127

Intervention type: PROCEDURE
Intervention: Dynamic contrast enhancement MRI
Study: NCT03617679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rucaparib
Description: Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
Study: NCT00580905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion.
Study: NCT02486406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir mini tablet
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir mini tablet
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir mini tablet
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir mini tablet
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir mini tablet
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir mini tablet
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir mini tablet
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir mini tablet
Description: Film-coated tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin solution
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin solution
Description: Oral solution
Study: NCT03158558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated, Multi-Couple Group CBCT for PTSD
Description: Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson \& Fredman, 2012)
Study: NCT02322697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of L-carnitine
Description: Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
Study: NCT02034500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 1790GAHB

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04770194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8008 Prototype Capsule A
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8008 Prototype Capsule A
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8008 Prototype Capsule A
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8008 Prototype Capsule B
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8008 Prototype Capsule B
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8008 Prototype Capsule B
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT02470962

Intervention type: OTHER
Intervention: Observation
Description: Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
Study: NCT04837274

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose (480 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: Tary Cherry (480 mg)
Study: NCT00550355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: 3 doses of PD 0360324 (Dose level 1) administered over 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: 3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
Study: NCT01744730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
Study: NCT04489888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
Study: NCT04489888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
Study: NCT01975389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bococizumab (PF-04950615)
Description: 150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Study: NCT03550963

Intervention type: OTHER
Group type: OTHER
Intervention: rice-richen meal
Description: Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.

Intervention type: OTHER
Group type: OTHER
Intervention: wheaten-richen meal
Description: Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
Study: NCT00874744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25mg bevacizumab (0.05ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Description: 4.0 mg Triamcinolone acetonide injection
Study: NCT01485952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196 (Low Dose)
Description: 10 mg once daily administration (immediate release capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196 (High Dose)
Description: 100 mg once daily administration (immediate release capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily administration (immediate release capsule)
Study: NCT00078390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-3304
Description: S-3304 will be administered at the tolerable dose BID along with chemo-irradiation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-irradiation
Description: Standard of care chemo-irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemo-irradiation
Description: Standard of care chemo-irradiation
Study: NCT04300400

Intervention type: OTHER
Intervention: Delphi questionnaire
Description: Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
Study: NCT04983147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-training follow-up
Description: After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days.